Cytogenetics and Prognostic Models in Myelodysplastic Syndromes

Uma Borate, Harry P. Erba

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Myelodysplastic syndromes (MDS), discussed in this chapter, are a heterogeneous group of clonal hematopoietic disorders that have an increased risk of progression to acute myeloid leukemia (AML). The prognosis of MDS patients varies significantly based on both patient and disease characteristics. Various classifications have been proposed to better prognosticate patient outcomes. The French-American-British (FAB) classification is the oldest scheme for classifying MDS, dividing it into five subtypes. The World Health Organization (WHO) reclassified MDS in 2000 and 2008 based on clinical data, but the system remained predominantly a morphologic classification. Today, the most widely accepted MDS prognostic models are based predominantly on marrow morphology, cytogenetics, and cytopenias. However, prognostic models are only valid in the context of available therapies and thus have limited use, basically just identifying patients with high-risk disease who should proceed to allogeneic hematopoietic stem cell transplantation, if possible. Our knowledge of both somatic mutations and epigenetic abnormalities in this disease is increasing rapidly, and these findings are likely to be incorporated into future prognostic models and may help guide therapeutic options.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley-Blackwell
Pages106-112
Number of pages7
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

    Fingerprint

Keywords

  • Clonal hematopoietic disorders
  • French-American-British (FAB) classification of MDS
  • MDS prognostic models
  • Myelodysplastic syndromes (MDS)
  • World Health Organization (WHO) classification of MDS

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Borate, U., & Erba, H. P. (2014). Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. In Cancer Consult: Expertise for Clinical Practice (pp. 106-112). Wiley-Blackwell. https://doi.org/10.1002/9781118589199.ch15